These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 24876763)

  • 1. The efficacy of bromfenac ophthalmic solution 0.07% dosed once daily in achieving zero-to-trace anterior chamber cell severity following cataract surgery.
    Silverstein SM; Jackson MA; Goldberg DF; Muñoz M
    Clin Ophthalmol; 2014; 8():965-72. PubMed ID: 24876763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bromfenac ophthalmic solution 0.07% dosed once daily for cataract surgery: results of 2 randomized controlled trials.
    Walters TR; Goldberg DF; Peace JH; Gow JA;
    Ophthalmology; 2014 Jan; 121(1):25-33. PubMed ID: 24021896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of bromfenac ophthalmic solution (Bromday) dosed once daily for postoperative ocular inflammation and pain.
    Henderson BA; Gayton JL; Chandler SP; Gow JA; Klier SM; McNamara TR;
    Ophthalmology; 2011 Nov; 118(11):2120-7. PubMed ID: 21762992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Once daily dosing of bromfenac ophthalmic solution 0.09% for postoperative ocular inflammation and pain.
    Silverstein SM; Cable MG; Sadri E; Peace JH; Fong R; Chandler SP; Gow JA; Klier SM; McNamara TR;
    Curr Med Res Opin; 2011 Sep; 27(9):1693-703. PubMed ID: 21751945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bromfenac ophthalmic solution 0.09% (Xibrom) for postoperative ocular pain and inflammation.
    Donnenfeld ED; Holland EJ; Stewart RH; Gow JA; Grillone LR;
    Ophthalmology; 2007 Sep; 114(9):1653-62. PubMed ID: 17445902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Once-Daily Bromfenac 0.07% Versus Once-Daily Nepafenac 0.3% in Patients Undergoing Phacoemulsification.
    Toyos MM
    Ophthalmol Ther; 2019 Jun; 8(2):261-270. PubMed ID: 30868419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The systemic safety of bromfenac ophthalmic solution 0.09%.
    Stewart RH; Grillone LR; Shiffman ML; Donnenfeld ED; Gow JA;
    J Ocul Pharmacol Ther; 2007 Dec; 23(6):601-12. PubMed ID: 18001250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bromfenac Ophthalmic Solution 0.07% Versus Nepafenac Ophthalmic Suspension 0.3% for Post-Cataract Surgery Inflammation: A Pilot Study of Identical Dosing Regimens with Pre-Surgical "Pulse" Dose.
    Silverstein SM
    Ophthalmol Ther; 2019 Dec; 8(4):577-587. PubMed ID: 31552543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized double-masked study to compare the ocular safety, tolerability, and efficacy of bromfenac 0.075% compared with vehicle in cataract surgery subjects.
    Hosseini K; Walters T; DaVanzo R; Lindstrom RL
    Clin Ophthalmol; 2016; 10():2311-2317. PubMed ID: 27920490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anterior Chamber Inflammation After Cataract Surgery: A Randomized Clinical Trial Comparing Bromfenac 0.09% to Dexamethasone 0.1.
    Coassin M; De Maria M; Mastrofilippo V; Braglia L; Cimino L; Sartori A; Fontana L
    Adv Ther; 2019 Oct; 36(10):2712-2722. PubMed ID: 31482510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of bromfenac 0.09% QD to nepafenac 0.1% TID after cataract surgery: pilot evaluation of visual acuity, macular volume, and retinal thickness at a single site.
    Cable M
    Clin Ophthalmol; 2012; 6():997-1004. PubMed ID: 22815642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative evaluation of once-daily and twice-daily dosing of topical bromfenac 0.09%: aqueous pharmacokinetics and clinical efficacy study.
    Titiyal JS; Thangavel R; Kaur M; Venkatesh P; Velpandian T; Sinha R
    J Cataract Refract Surg; 2021 Sep; 47(9):1115-1121. PubMed ID: 34468447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of bromfenac ophthalmic solution on ocular inflammation following cataract surgery.
    Miyanaga M; Miyai T; Nejima R; Maruyama Y; Miyata K; Kato S
    Acta Ophthalmol; 2009 May; 87(3):300-5. PubMed ID: 19183412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bromfenac Ophthalmic Solution 0.07%: A Review of Its Use After Cataract Surgery.
    Hoy SM
    Clin Drug Investig; 2015 Aug; 35(8):525-9. PubMed ID: 26177719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Comparative Efficacy and Tolerability of Diclofenac 0.1% and Bromfenac 0.09% Ophthalmic Solutions after Cataract Surgery.
    Giannaccare G; Finzi A; Sebastiani S; Greco F; Versura P; Campos EC
    Curr Eye Res; 2018 Dec; 43(12):1445-1453. PubMed ID: 30009640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bromfenac ophthalmic solution 0.09% as an adjunctive therapy to topical steroids after cataract surgery in pseudoexfoliation syndrome.
    Coassin M; Iovieno A; Soldani A; Cavuto S; Cimino L; Sartori A; Formisano D; Fontana L
    J Cataract Refract Surg; 2016 Aug; 42(8):1119-25. PubMed ID: 27531286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A double-masked, placebo-controlled evaluation of 0.5% loteprednol etabonate in the treatment of postoperative inflammation. The Loteprednol Etabonate Postoperative Inflammation Study Group 2.
    Ophthalmology; 1998 Sep; 105(9):1780-6. PubMed ID: 9754192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of 2 regimens of loteprednol etabonate and bromfenac for cataract surgery.
    Al-Awadi A; Tokko HA; Chan CC; Somani S
    Can J Ophthalmol; 2019 Jun; 54(3):388-394. PubMed ID: 31109481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dexamethasone Intracameral Drug-Delivery Suspension for Inflammation Associated with Cataract Surgery: A Randomized, Placebo-Controlled, Phase III Trial.
    Donnenfeld E; Holland E
    Ophthalmology; 2018 Jun; 125(6):799-806. PubMed ID: 29397189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Twice-Daily vs. Once-Daily Dosing with 0.075% Bromfenac in DuraSite: Outcomes from a 14-Day Phase 2 Study.
    Trattler W; Hosseini K
    Ophthalmol Ther; 2017 Dec; 6(2):277-284. PubMed ID: 28819932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.